Oral contraceptives and premenopausal breast cancer in nulliparous women

Bruce V. Stadel, Shenghan Lai, James J. Schlesselman, Pamela Murray

Research output: Contribution to journalArticle

Abstract

Characteristics of women with potential for modifying the relationship between use of oral contraceptives (OCs) and the risk of premenopausal breast cancer were investigated using data from the Cancer and Steroid Hormone study, a populationdashbased, case-control study conducted in eight geographic areas of the United States. Cases consisted of 2945 women who were premenopausal and 20-54 years of age when breast cancer was diagnosed between December 1, 1980, and December 31, 1982; controls consisted of 2646 women with no history of breast cancer who were also premenopausal and 20-54 years of age when selected during the same period. Results are presented with the cases and controls divided into eight groups on the basis of age at diagnosis on selection (20-44, 45-54), parity (0, ≥1), and age at menarche (2-3 years of use (95% confidence intervals 0.7-2.4), 1.3 for 4-7 years (95% CI 0.7-2.6), 2.7 for 8-11 years (95% CI 1.2-6.3), and 11.8 for 12 years or longer (95% CI 1.4-95.7). OC use is not significantly related to the risk of breast cancer among women in any of the other seven groups. These findings suggest that prolonged OC use may accelerate the onset of breast cancer for a small group of susceptible women while having no appreciable impact on overall risk. The findings should be regarded as tentative, however, since they are based upon numerous comparisons and because age of menarche was stratified at 13 years to highlight the concentration of breast cancer risk apparent in our data.

Original languageEnglish (US)
Pages (from-to)287-299
Number of pages13
JournalContraception
Volume38
Issue number3
DOIs
StatePublished - 1988
Externally publishedYes

Fingerprint

Oral Contraceptives
Breast Neoplasms
Menarche
Parity
Case-Control Studies
Steroids
Hormones
Confidence Intervals
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Oral contraceptives and premenopausal breast cancer in nulliparous women. / Stadel, Bruce V.; Lai, Shenghan; Schlesselman, James J.; Murray, Pamela.

In: Contraception, Vol. 38, No. 3, 1988, p. 287-299.

Research output: Contribution to journalArticle

Stadel, Bruce V. ; Lai, Shenghan ; Schlesselman, James J. ; Murray, Pamela. / Oral contraceptives and premenopausal breast cancer in nulliparous women. In: Contraception. 1988 ; Vol. 38, No. 3. pp. 287-299.
@article{53c824b4e6de43f78c9578491d3f2985,
title = "Oral contraceptives and premenopausal breast cancer in nulliparous women",
abstract = "Characteristics of women with potential for modifying the relationship between use of oral contraceptives (OCs) and the risk of premenopausal breast cancer were investigated using data from the Cancer and Steroid Hormone study, a populationdashbased, case-control study conducted in eight geographic areas of the United States. Cases consisted of 2945 women who were premenopausal and 20-54 years of age when breast cancer was diagnosed between December 1, 1980, and December 31, 1982; controls consisted of 2646 women with no history of breast cancer who were also premenopausal and 20-54 years of age when selected during the same period. Results are presented with the cases and controls divided into eight groups on the basis of age at diagnosis on selection (20-44, 45-54), parity (0, ≥1), and age at menarche (2-3 years of use (95{\%} confidence intervals 0.7-2.4), 1.3 for 4-7 years (95{\%} CI 0.7-2.6), 2.7 for 8-11 years (95{\%} CI 1.2-6.3), and 11.8 for 12 years or longer (95{\%} CI 1.4-95.7). OC use is not significantly related to the risk of breast cancer among women in any of the other seven groups. These findings suggest that prolonged OC use may accelerate the onset of breast cancer for a small group of susceptible women while having no appreciable impact on overall risk. The findings should be regarded as tentative, however, since they are based upon numerous comparisons and because age of menarche was stratified at 13 years to highlight the concentration of breast cancer risk apparent in our data.",
author = "Stadel, {Bruce V.} and Shenghan Lai and Schlesselman, {James J.} and Pamela Murray",
year = "1988",
doi = "10.1016/0010-7824(88)90101-1",
language = "English (US)",
volume = "38",
pages = "287--299",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Oral contraceptives and premenopausal breast cancer in nulliparous women

AU - Stadel, Bruce V.

AU - Lai, Shenghan

AU - Schlesselman, James J.

AU - Murray, Pamela

PY - 1988

Y1 - 1988

N2 - Characteristics of women with potential for modifying the relationship between use of oral contraceptives (OCs) and the risk of premenopausal breast cancer were investigated using data from the Cancer and Steroid Hormone study, a populationdashbased, case-control study conducted in eight geographic areas of the United States. Cases consisted of 2945 women who were premenopausal and 20-54 years of age when breast cancer was diagnosed between December 1, 1980, and December 31, 1982; controls consisted of 2646 women with no history of breast cancer who were also premenopausal and 20-54 years of age when selected during the same period. Results are presented with the cases and controls divided into eight groups on the basis of age at diagnosis on selection (20-44, 45-54), parity (0, ≥1), and age at menarche (2-3 years of use (95% confidence intervals 0.7-2.4), 1.3 for 4-7 years (95% CI 0.7-2.6), 2.7 for 8-11 years (95% CI 1.2-6.3), and 11.8 for 12 years or longer (95% CI 1.4-95.7). OC use is not significantly related to the risk of breast cancer among women in any of the other seven groups. These findings suggest that prolonged OC use may accelerate the onset of breast cancer for a small group of susceptible women while having no appreciable impact on overall risk. The findings should be regarded as tentative, however, since they are based upon numerous comparisons and because age of menarche was stratified at 13 years to highlight the concentration of breast cancer risk apparent in our data.

AB - Characteristics of women with potential for modifying the relationship between use of oral contraceptives (OCs) and the risk of premenopausal breast cancer were investigated using data from the Cancer and Steroid Hormone study, a populationdashbased, case-control study conducted in eight geographic areas of the United States. Cases consisted of 2945 women who were premenopausal and 20-54 years of age when breast cancer was diagnosed between December 1, 1980, and December 31, 1982; controls consisted of 2646 women with no history of breast cancer who were also premenopausal and 20-54 years of age when selected during the same period. Results are presented with the cases and controls divided into eight groups on the basis of age at diagnosis on selection (20-44, 45-54), parity (0, ≥1), and age at menarche (2-3 years of use (95% confidence intervals 0.7-2.4), 1.3 for 4-7 years (95% CI 0.7-2.6), 2.7 for 8-11 years (95% CI 1.2-6.3), and 11.8 for 12 years or longer (95% CI 1.4-95.7). OC use is not significantly related to the risk of breast cancer among women in any of the other seven groups. These findings suggest that prolonged OC use may accelerate the onset of breast cancer for a small group of susceptible women while having no appreciable impact on overall risk. The findings should be regarded as tentative, however, since they are based upon numerous comparisons and because age of menarche was stratified at 13 years to highlight the concentration of breast cancer risk apparent in our data.

UR - http://www.scopus.com/inward/record.url?scp=0023722774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023722774&partnerID=8YFLogxK

U2 - 10.1016/0010-7824(88)90101-1

DO - 10.1016/0010-7824(88)90101-1

M3 - Article

C2 - 3168449

AN - SCOPUS:0023722774

VL - 38

SP - 287

EP - 299

JO - Contraception

JF - Contraception

SN - 0010-7824

IS - 3

ER -